{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T13:45:05Z","timestamp":1792763105298,"version":"4.5.0"},"reference-count":74,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2023,2,1]],"date-time":"2023-02-01T00:00:00Z","timestamp":1675209600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,2,1]],"date-time":"2023-02-01T00:00:00Z","timestamp":1675209600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,12,8]],"date-time":"2022-12-08T00:00:00Z","timestamp":1670457600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100004339","name":"Sanofi","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004339","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Molecular Genetics and Metabolism"],"published-print":{"date-parts":[[2023,2]]},"DOI":"10.1016\/j.ymgme.2022.106967","type":"journal-article","created":{"date-parts":[[2022,11,30]],"date-time":"2022-11-30T11:26:00Z","timestamp":1669807560000},"page":"106967","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":32,"title":["Clinical outcomes among young patients with Fabry disease who initiated agalsidase beta treatment before 30 years of age: An analysis from the Fabry Registry"],"prefix":"10.1016","volume":"138","author":[{"given":"Robert J.","family":"Hopkin","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gustavo H.","family":"Cabrera","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John L.","family":"Jefferies","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Meng","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elvira","family":"Ponce","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eva","family":"Brand","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ulla","family":"Feldt-Rasmussen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dominique P.","family":"Germain","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nathalie","family":"Guffon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ana","family":"Jovanovic","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ilkka","family":"Kantola","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amel","family":"Karaa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ana M.","family":"Martins","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Camilla","family":"T\u00f8ndel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"William R.","family":"Wilcox","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Han-Wook","family":"Yoo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alessandro P.","family":"Burlina","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Mauer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ymgme.2022.106967_bb0005","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1186\/1750-1172-5-30","article-title":"Fabry disease","volume":"5","author":"Germain","year":"2010","journal-title":"Orphanet J. Rare Dis."},{"issue":"4","key":"10.1016\/j.ymgme.2022.106967_bb0010","doi-asserted-by":"crossref","first-page":"416","DOI":"10.1016\/j.ymgme.2018.02.014","article-title":"Fabry disease revisited: management and treatment recommendations for adult patients","volume":"123","author":"Ortiz","year":"2018","journal-title":"Mol. Genet. Metab."},{"key":"10.1016\/j.ymgme.2022.106967_bb0015","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1016\/j.cca.2014.08.002","article-title":"Urinary biomarker investigation in children with Fabry disease using tandem mass spectrometry","volume":"438","author":"Auray-Blais","year":"2015","journal-title":"Clin. Chim. Acta"},{"issue":"13","key":"10.1016\/j.ymgme.2022.106967_bb0020","doi-asserted-by":"crossref","first-page":"1530","DOI":"10.2174\/0929867324666170616102112","article-title":"Biomarkers for diagnosing and staging of Fabry disease","volume":"25","author":"Kr\u00e4mer","year":"2018","journal-title":"Curr. Med. Chem."},{"key":"10.1016\/j.ymgme.2022.106967_bb0025","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1186\/1750-1172-8-116","article-title":"Fibrosis: a key feature of Fabry disease with potential therapeutic implications","volume":"8","author":"Weidemann","year":"2013","journal-title":"Orphanet J. Rare Dis."},{"issue":"4","key":"10.1016\/j.ymgme.2022.106967_bb0030","doi-asserted-by":"crossref","first-page":"610","DOI":"10.1016\/j.humpath.2011.07.020","article-title":"Histologic abnormalities of placental tissues in Fabry disease: a case report and review of the literature","volume":"43","author":"Thurberg","year":"2012","journal-title":"Hum. Pathol."},{"issue":"1","key":"10.1016\/j.ymgme.2022.106967_bb0035","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1111\/j.1447-0756.1985.tb00045.x","article-title":"Early prenatal diagnosis of inborn error of metabolism: a case report of a fetus affected with Fabry's disease","volume":"11","author":"Tsutsumi","year":"1985","journal-title":"Asia Oceania J. Obstet. Gynaecol."},{"issue":"1","key":"10.1016\/j.ymgme.2022.106967_bb0040","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1159\/000369309","article-title":"Foot process effacement is an early marker of nephropathy in young classic Fabry patients without albuminuria","volume":"129","author":"T\u00f8ndel","year":"2015","journal-title":"Nephron"},{"issue":"5","key":"10.1016\/j.ymgme.2022.106967_bb0045","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1038\/gim.2014.120","article-title":"Fabry disease in infancy and early childhood: a systematic literature review","volume":"17","author":"Laney","year":"2015","journal-title":"Genet. Med."},{"key":"10.1016\/j.ymgme.2022.106967_bb0050","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1186\/1471-2350-3-10","article-title":"Patients affected with Fabry disease have an increased incidence of progressive hearing loss and sudden deafness: an investigation of twenty-two hemizygous male patients","volume":"3","author":"Germain","year":"2002","journal-title":"BMC Med. Genet."},{"issue":"6","key":"10.1016\/j.ymgme.2022.106967_bb0055","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1097\/AJP.0b013e318074c986","article-title":"Nature and prevalence of pain in Fabry disease and its response to enzyme replacement therapy\u2013a retrospective analysis from the Fabry Outcome Survey","volume":"23","author":"Hoffmann","year":"2007","journal-title":"Clin. J. Pain"},{"issue":"12","key":"10.1016\/j.ymgme.2022.106967_bb0060","doi-asserted-by":"crossref","first-page":"1447","DOI":"10.1016\/j.cgh.2007.08.012","article-title":"Gastrointestinal symptoms in 342 patients with Fabry disease: prevalence and response to enzyme replacement therapy","volume":"5","author":"Hoffmann","year":"2007","journal-title":"Clin. Gastroenterol. Hepatol."},{"issue":"5","key":"10.1016\/j.ymgme.2022.106967_bb0065","doi-asserted-by":"crossref","first-page":"550","DOI":"10.1203\/PDR.0b013e318183f132","article-title":"Characterization of Fabry disease in 352 pediatric patients in the Fabry Registry","volume":"64","author":"Hopkin","year":"2008","journal-title":"Pediatr. Res."},{"issue":"5","key":"10.1016\/j.ymgme.2022.106967_bb0070","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1111\/j.1399-0004.2011.01671.x","article-title":"Fabry disease in children and response to enzyme replacement therapy: results from the Fabry Outcome Survey","volume":"81","author":"Ramaswami","year":"2012","journal-title":"Clin. Genet."},{"issue":"5","key":"10.1016\/j.ymgme.2022.106967_bb0075","doi-asserted-by":"crossref","first-page":"1631","DOI":"10.1681\/ASN.2016090964","article-title":"Characterization of classical and nonclassical Fabry disease: a multicenter study","volume":"28","author":"Arends","year":"2017","journal-title":"J. Am. Soc. Nephrol."},{"issue":"8","key":"10.1016\/j.ymgme.2022.106967_bb0080","doi-asserted-by":"crossref","first-page":"548","DOI":"10.1136\/jmg.2008.065904","article-title":"Natural course of Fabry disease: changing pattern of causes of death in FOS - Fabry Outcome Survey","volume":"46","author":"Mehta","year":"2009","journal-title":"J. Med. Genet."},{"issue":"11","key":"10.1016\/j.ymgme.2022.106967_bb0085","doi-asserted-by":"crossref","first-page":"790","DOI":"10.1097\/GIM.0b013e3181bb05bb","article-title":"Life expectancy and cause of death in males and females with Fabry disease: findings from the Fabry Registry","volume":"11","author":"Waldek","year":"2009","journal-title":"Genet. Med."},{"issue":"1","key":"10.1016\/j.ymgme.2022.106967_bb0090","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1111\/cge.12613","article-title":"X-chromosome inactivation in female patients with Fabry disease","volume":"89","author":"Echevarria","year":"2016","journal-title":"Clin. Genet."},{"issue":"2","key":"10.1016\/j.ymgme.2022.106967_bb0095","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1016\/j.ymgme.2007.09.013","article-title":"Females with Fabry disease frequently have major organ involvement: lessons from the Fabry registry","volume":"93","author":"Wilcox","year":"2008","journal-title":"Mol. Genet. Metab."},{"issue":"4","key":"10.1016\/j.ymgme.2022.106967_bb0100","doi-asserted-by":"crossref","first-page":"390","DOI":"10.1111\/cge.14102","article-title":"Challenging the traditional approach for interpreting genetic variants: lessons from Fabry disease","volume":"101","author":"Germain","year":"2022","journal-title":"Clin. Genet."},{"key":"10.1016\/j.ymgme.2022.106967_bb0105","series-title":"Fabrazyme [Prescribing Information]","year":"2021"},{"key":"10.1016\/j.ymgme.2022.106967_bb0110","series-title":"Fabrazyme [Summary of Product Characteristics]","year":"2021"},{"key":"10.1016\/j.ymgme.2022.106967_bb0115","series-title":"Replagal [Summary of Product Characteristics]","year":"2021"},{"issue":"4","key":"10.1016\/j.ymgme.2022.106967_bb0120","doi-asserted-by":"crossref","first-page":"430","DOI":"10.1038\/gim.2016.122","article-title":"The validation of pharmacogenetics for the identification of Fabry patients to be treated with migalastat","volume":"19","author":"Benjamin","year":"2017","journal-title":"Genet. Med."},{"key":"10.1016\/j.ymgme.2022.106967_bb0125","series-title":"Galafold [Prescribing Information]","year":"2020"},{"key":"10.1016\/j.ymgme.2022.106967_bb0130","series-title":"Galafold [Summary of Product Characteristics]","year":"2021"},{"issue":"2","key":"10.1016\/j.ymgme.2022.106967_bb0135","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1016\/j.ymgme.2017.05.001","article-title":"Favourable effect of early versus late start of enzyme replacement therapy on plasma globotriaosylsphingosine levels in men with classical Fabry disease","volume":"121","author":"Arends","year":"2017","journal-title":"Mol. Genet. Metab."},{"issue":"2","key":"10.1016\/j.ymgme.2022.106967_bb0140","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1111\/cge.13546","article-title":"Consensus recommendations for diagnosis, management and treatment of Fabry disease in paediatric patients","volume":"96","author":"Germain","year":"2019","journal-title":"Clin. Genet."},{"issue":"2","key":"10.1016\/j.ymgme.2022.106967_bb0145","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1016\/j.ymgme.2015.10.007","article-title":"The management and treatment of children with Fabry disease: a United States-based perspective","volume":"117","author":"Hopkin","year":"2016","journal-title":"Mol. Genet. Metab."},{"issue":"3","key":"10.1016\/j.ymgme.2022.106967_bb0150","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1016\/j.ymgme.2018.06.004","article-title":"European expert consensus statement on therapeutic goals in Fabry disease","volume":"124","author":"Wanner","year":"2018","journal-title":"Mol. Genet. Metab."},{"issue":"3","key":"10.1016\/j.ymgme.2022.106967_bb0155","doi-asserted-by":"crossref","first-page":"212","DOI":"10.1016\/j.ymgme.2018.04.007","article-title":"The effect of enzyme replacement therapy on clinical outcomes in paediatric patients with Fabry disease - a systematic literature review by a European panel of experts","volume":"126","author":"Spada","year":"2019","journal-title":"Mol. Genet. Metab."},{"issue":"3","key":"10.1016\/j.ymgme.2022.106967_bb0160","doi-asserted-by":"crossref","first-page":"224","DOI":"10.1016\/j.ymgme.2018.09.007","article-title":"The effect of enzyme replacement therapy on clinical outcomes in female patients with Fabry disease - a systematic literature review by a European panel of experts","volume":"126","author":"Germain","year":"2019","journal-title":"Mol. Genet. Metab."},{"key":"10.1016\/j.ymgme.2022.106967_bb0165","first-page":"100454","article-title":"The effect of enzyme replacement therapy on clinical outcomes in male patients with Fabry disease: a systematic literature review by a European panel of experts","volume":"19","author":"Germain","year":"2019","journal-title":"Mol. Genet. Metab. Rep."},{"issue":"3","key":"10.1016\/j.ymgme.2022.106967_bb0170","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pmed.1001979","article-title":"Comparison of the Schwartz and CKD-EPI equations for estimating glomerular filtration rate in children, adolescents, and adults: a retrospective cross-sectional study","volume":"13","author":"Selistre","year":"2016","journal-title":"PLoS Med."},{"issue":"6","key":"10.1016\/j.ymgme.2022.106967_bb0175","doi-asserted-by":"crossref","first-page":"989","DOI":"10.1681\/ASN.2011070705","article-title":"GFR estimation in adolescents and young adults","volume":"23","author":"Selistre","year":"2012","journal-title":"J. Am. Soc. Nephrol."},{"issue":"3","key":"10.1016\/j.ymgme.2022.106967_bb0180","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1681\/ASN.2008030287","article-title":"New equations to estimate GFR in children with CKD","volume":"20","author":"Schwartz","year":"2009","journal-title":"J. Am. Soc. Nephrol."},{"key":"10.1016\/j.ymgme.2022.106967_bb0185","series-title":"Applied Longitudinal Analysis","author":"Fitzmaurice","year":"2011"},{"issue":"Suppl. 2","key":"10.1016\/j.ymgme.2022.106967_bb0190","first-page":"337","article-title":"2012 clinical practice guideline for the management of blood pressure in chronic kidney disease","author":"KDIGO","year":"2012","journal-title":"Kidney Int."},{"issue":"6","key":"10.1016\/j.ymgme.2022.106967_bb0195","doi-asserted-by":"crossref","first-page":"1959","DOI":"10.1681\/ASN.2006101081","article-title":"Progression risk, urinary protein excretion, and treatment effects of angiotensin-converting enzyme inhibitors in nondiabetic kidney disease","volume":"18","author":"Kent","year":"2007","journal-title":"J. Am. Soc. Nephrol."},{"issue":"3","key":"10.1016\/j.ymgme.2022.106967_bb0200","doi-asserted-by":"crossref","first-page":"382","DOI":"10.2215\/CJN.03080314","article-title":"A systematic review of glomerular hyperfiltration assessment and definition in the medical literature","volume":"10","author":"Cachat","year":"2015","journal-title":"Clin. J. Am. Soc. Nephrol."},{"issue":"11","key":"10.1016\/j.ymgme.2022.106967_bb0205","doi-asserted-by":"crossref","DOI":"10.1161\/CIRCIMAGING.117.006979","article-title":"Relationship of echocardiographic Z scores adjusted for body surface area to age, sex, race, and ethnicity: the Pediatric Heart Network normal echocardiogram database","volume":"10","author":"Lopez","year":"2017","journal-title":"Circ. Cardiovasc. Imaging"},{"issue":"8","key":"10.1016\/j.ymgme.2022.106967_bb0210","doi-asserted-by":"crossref","first-page":"922","DOI":"10.1016\/j.echo.2008.02.006","article-title":"Regression equations for calculation of z scores of cardiac structures in a large cohort of healthy infants, children, and adolescents: an echocardiographic study","volume":"21","author":"Pettersen","year":"2008","journal-title":"J. Am. Soc. Echocardiogr."},{"issue":"1","key":"10.1016\/j.ymgme.2022.106967_bb0215","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1016\/j.ymgme.2019.03.010","article-title":"Low-dose agalsidase beta treatment in male pediatric patients with Fabry disease: a 5-year randomized controlled trial","volume":"127","author":"Ramaswami","year":"2019","journal-title":"Mol. Genet. Metab."},{"issue":"2","key":"10.1016\/j.ymgme.2022.106967_bb0220","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1016\/j.ymgme.2021.12.004","article-title":"Early start of enzyme replacement therapy in pediatric male patients with classical Fabry disease is associated with attenuated disease progression","volume":"135","author":"van der Veen","year":"2022","journal-title":"Mol. Genet. Metab."},{"issue":"7","key":"10.1016\/j.ymgme.2022.106967_bb0225","doi-asserted-by":"crossref","first-page":"2102","DOI":"10.1093\/ndt\/gfp031","article-title":"Fabry disease: progression of nephropathy, and prevalence of cardiac and cerebrovascular events before enzyme replacement therapy","volume":"24","author":"Schiffmann","year":"2009","journal-title":"Nephrol. Dial. Transplant."},{"issue":"6","key":"10.1016\/j.ymgme.2022.106967_bb0230","doi-asserted-by":"crossref","first-page":"663","DOI":"10.1038\/ki.2010.484","article-title":"Progressive podocyte injury and globotriaosylceramide (GL-3) accumulation in young patients with Fabry disease","volume":"79","author":"Najafian","year":"2011","journal-title":"Kidney Int."},{"issue":"11","key":"10.1016\/j.ymgme.2022.106967_bb0235","doi-asserted-by":"crossref","first-page":"2095","DOI":"10.1007\/s00467-018-4006-3","article-title":"Clinical parameters, lysoGb3, podocyturia, and kidney biopsy in children with Fabry disease: is a correlation possible?","volume":"33","author":"Politei","year":"2018","journal-title":"Pediatr. Nephrol."},{"issue":"2","key":"10.1016\/j.ymgme.2022.106967_bb0240","doi-asserted-by":"crossref","first-page":"365","DOI":"10.2215\/CJN.08091109","article-title":"Assessment of renal pathology and dysfunction in children with Fabry disease","volume":"5","author":"Ramaswami","year":"2010","journal-title":"Clin. J. Am. Soc. Nephrol."},{"issue":"5","key":"10.1016\/j.ymgme.2022.106967_bb0245","doi-asserted-by":"crossref","first-page":"767","DOI":"10.1053\/j.ajkd.2007.12.032","article-title":"Renal biopsy findings in children and adolescents with Fabry disease and minimal albuminuria","volume":"51","author":"T\u00f8ndel","year":"2008","journal-title":"Am. J. Kidney Dis."},{"issue":"9","key":"10.1016\/j.ymgme.2022.106967_bb0250","doi-asserted-by":"crossref","first-page":"1525","DOI":"10.1093\/ndt\/gfy357","article-title":"Age-related renal function decline in Fabry disease patients on enzyme replacement therapy: a longitudinal cohort study","volume":"34","author":"Madsen","year":"2019","journal-title":"Nephrol. Dial. Transplant."},{"issue":"12","key":"10.1016\/j.ymgme.2022.106967_bb0255","doi-asserted-by":"crossref","first-page":"2220","DOI":"10.2215\/CJN.04340510","article-title":"Prognostic indicators of renal disease progression in adults with Fabry disease: natural history data from the Fabry Registry","volume":"5","author":"Wanner","year":"2010","journal-title":"Clin. J. Am. Soc. Nephrol."},{"issue":"3","key":"10.1016\/j.ymgme.2022.106967_bb0260","doi-asserted-by":"crossref","first-page":"1042","DOI":"10.1093\/ndt\/gfr420","article-title":"Renal outcomes of agalsidase beta treatment for Fabry disease: role of proteinuria and timing of treatment initiation","volume":"27","author":"Warnock","year":"2012","journal-title":"Nephrol. Dial. Transplant."},{"issue":"12","key":"10.1016\/j.ymgme.2022.106967_bb0265","doi-asserted-by":"crossref","first-page":"860","DOI":"10.1136\/jmedgenet-2015-103471","article-title":"Antiproteinuric therapy and Fabry nephropathy: factors associated with preserved kidney function during agalsidase-beta therapy","volume":"52","author":"Warnock","year":"2015","journal-title":"J. Med. Genet."},{"issue":"4","key":"10.1016\/j.ymgme.2022.106967_bb0270","doi-asserted-by":"crossref","first-page":"865","DOI":"10.1681\/ASN.2019050497","article-title":"Accumulation of globotriaosylceramide in podocytes in Fabry nephropathy is associated with progressive podocyte loss","volume":"31","author":"Najafian","year":"2020","journal-title":"J. Am. Soc. Nephrol."},{"issue":"5","key":"10.1016\/j.ymgme.2022.106967_bb0275","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1136\/jmedgenet-2014-102797","article-title":"Ten-year outcome of enzyme replacement therapy with agalsidase beta in patients with Fabry disease","volume":"52","author":"Germain","year":"2015","journal-title":"J. Med. Genet."},{"issue":"5","key":"10.1016\/j.ymgme.2022.106967_bb0280","doi-asserted-by":"crossref","first-page":"1547","DOI":"10.1681\/ASN.2006080816","article-title":"Sustained, long-term renal stabilization after 54 months of agalsidase beta therapy in patients with Fabry disease","volume":"18","author":"Germain","year":"2007","journal-title":"J. Am. Soc. Nephrol."},{"key":"10.1016\/j.ymgme.2022.106967_bb0285","doi-asserted-by":"crossref","first-page":"2149","DOI":"10.2147\/DDDT.S249433","article-title":"Analysis of renal and cardiac outcomes in male participants in the Fabry Outcome Survey starting agalsidase alfa enzyme replacement therapy before and after 18 years of age","volume":"14","author":"Parini","year":"2020","journal-title":"Drug Des. Devel. Ther."},{"issue":"5","key":"10.1016\/j.ymgme.2022.106967_bb0290","doi-asserted-by":"crossref","first-page":"1507","DOI":"10.1093\/ndt\/gfp658","article-title":"Monitoring renal function in children with Fabry disease: comparisons of measured and creatinine-based estimated glomerular filtration rate","volume":"25","author":"T\u00f8ndel","year":"2010","journal-title":"Nephrol. Dial. Transplant."},{"issue":"11","key":"10.1016\/j.ymgme.2022.106967_bb0295","doi-asserted-by":"crossref","first-page":"2368","DOI":"10.1111\/dom.13831","article-title":"Renal hyperfiltration defined by high estimated glomerular filtration rate: a risk factor for cardiovascular disease and mortality","volume":"21","author":"Kanbay","year":"2019","journal-title":"Diabetes Obes. Metab."},{"issue":"23","key":"10.1016\/j.ymgme.2022.106967_bb0300","doi-asserted-by":"crossref","first-page":"2473","DOI":"10.1056\/NEJMra054415","article-title":"Assessing kidney function\u2013measured and estimated glomerular filtration rate","volume":"354","author":"Stevens","year":"2006","journal-title":"N. Engl. J. Med."},{"issue":"1","key":"10.1016\/j.ymgme.2022.106967_bb0305","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1159\/000493469","article-title":"Glomerular hyperfiltration: an early marker of nephropathy in Fabry disease","volume":"141","author":"Riccio","year":"2019","journal-title":"Nephron"},{"issue":"7","key":"10.1016\/j.ymgme.2022.106967_bb0310","doi-asserted-by":"crossref","first-page":"1076","DOI":"10.1002\/ejhf.1960","article-title":"An expert consensus document on the management of cardiovascular manifestations of Fabry disease","volume":"22","author":"Linhart","year":"2020","journal-title":"Eur. J. Heart Fail."},{"key":"10.1016\/j.ymgme.2022.106967_bb0315","first-page":"53","article-title":"Early cardiac changes in children with Anderson-Fabry disease","volume":"11","author":"Havranek","year":"2013","journal-title":"JIMD Rep."},{"issue":"4","key":"10.1016\/j.ymgme.2022.106967_bb0320","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1111\/j.1651-2227.2008.00700.x","article-title":"Cardiac manifestations of Anderson-Fabry disease in children and adolescents","volume":"97","author":"Kampmann","year":"2008","journal-title":"Acta Paediatr."},{"issue":"2","key":"10.1016\/j.ymgme.2022.106967_bb0325","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1016\/j.amjcard.2017.04.016","article-title":"Arrhythmia and clinical cardiac findings in children with Anderson-Fabry disease","volume":"120","author":"Wilson","year":"2017","journal-title":"Am. J. Cardiol."},{"issue":"12","key":"10.1016\/j.ymgme.2022.106967_bb0330","doi-asserted-by":"crossref","first-page":"958","DOI":"10.1038\/gim.2013.53","article-title":"Analysis of left ventricular mass in untreated men and in men treated with agalsidase-beta: data from the Fabry Registry","volume":"15","author":"Germain","year":"2013","journal-title":"Genet. Med."},{"issue":"1","key":"10.1016\/j.ymgme.2022.106967_bb0335","doi-asserted-by":"crossref","first-page":"2027852","DOI":"10.1080\/19490976.2022.2027852","article-title":"Fabry disease - a multisystemic disease with gastrointestinal manifestations","volume":"14","author":"Lenders","year":"2022","journal-title":"Gut Microbes"},{"issue":"4","key":"10.1016\/j.ymgme.2022.106967_bb0340","doi-asserted-by":"crossref","first-page":"626","DOI":"10.1177\/1756283X16642936","article-title":"Understanding the gastrointestinal manifestations of Fabry disease: promoting prompt diagnosis","volume":"9","author":"Zar-Kessler","year":"2016","journal-title":"Ther. Adv. Gastroenterol."},{"issue":"2","key":"10.1016\/j.ymgme.2022.106967_bb0345","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1038\/ncpneuro0113","article-title":"Mechanisms of disease: neuropathic pain\u2013a clinical perspective","volume":"2","author":"Baron","year":"2006","journal-title":"Nat. Clin. Pract. Neurol."},{"issue":"7","key":"10.1016\/j.ymgme.2022.106967_bb0350","doi-asserted-by":"crossref","first-page":"436","DOI":"10.1111\/j.1445-5994.2007.01366.x","article-title":"Neurology of Fabry disease","volume":"37","author":"Low","year":"2007","journal-title":"Intern. Med. J."},{"issue":"7","key":"10.1016\/j.ymgme.2022.106967_bb0355","doi-asserted-by":"crossref","first-page":"568","DOI":"10.1111\/cns.12542","article-title":"Pain in Fabry disease: practical recommendations for diagnosis and treatment","volume":"22","author":"Politei","year":"2016","journal-title":"CNS Neurosci. Ther."},{"issue":"4","key":"10.1016\/j.ymgme.2022.106967_bb0360","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1016\/j.jpeds.2007.09.007","article-title":"Safety and efficacy of enzyme replacement therapy with agalsidase beta: an international, open-label study in pediatric patients with Fabry disease","volume":"152","author":"Wraith","year":"2008","journal-title":"J. Pediatr."},{"issue":"5","key":"10.1016\/j.ymgme.2022.106967_bb0365","doi-asserted-by":"crossref","first-page":"432","DOI":"10.1111\/j.1399-0004.2012.01947.x","article-title":"Fabry disease in children: agalsidase-beta enzyme replacement therapy","volume":"83","author":"Borgwardt","year":"2013","journal-title":"Clin. Genet."},{"issue":"7","key":"10.1016\/j.ymgme.2022.106967_bb0370","doi-asserted-by":"crossref","first-page":"1066","DOI":"10.1212\/01.WNL.0000118207.84514.40","article-title":"Enzyme replacement therapy improves function of C-, Adelta-, and Abeta-nerve fibers in Fabry neuropathy","volume":"62","author":"Hilz","year":"2004","journal-title":"Neurology"}],"container-title":["Molecular Genetics and Metabolism"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1096719222004437?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1096719222004437?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,21]],"date-time":"2025-10-21T23:52:47Z","timestamp":1761090767000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1096719222004437"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,2]]},"references-count":74,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2023,2]]}},"alternative-id":["S1096719222004437"],"URL":"https:\/\/doi.org\/10.1016\/j.ymgme.2022.106967","relation":{},"ISSN":["1096-7192"],"issn-type":[{"value":"1096-7192","type":"print"}],"subject":[],"published":{"date-parts":[[2023,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Clinical outcomes among young patients with Fabry disease who initiated agalsidase beta treatment before 30 years of age: An analysis from the Fabry Registry","name":"articletitle","label":"Article Title"},{"value":"Molecular Genetics and Metabolism","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ymgme.2022.106967","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 The Authors. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}],"article-number":"106967"}}